DCCR Fails to Reduce Excessive Appetite But Improves Other Measures, Data Show
Soleno Therapeutics’ investigational oral therapy diazoxide choline controlled-release (DCCR) failed to significantly lower excessive appetite, but it did improve body composition and behavior in Prader-Willi syndrome (PWS) patients, top-line data from a Phase 3 trial show. Notably, excessive appetite (hyperphagia) — the hallmark symptom of PWS —…